- Report
- September 2026
- 181 Pages
Global
From €3259EUR$3,545USD£2,771GBP
€3621EUR$3,939USD£3,079GBP
- Report
- September 2026
- 187 Pages
Global
From €3259EUR$3,545USD£2,771GBP
€3621EUR$3,939USD£3,079GBP
- Report
- March 2026
- 250 Pages
Global
From €4127EUR$4,490USD£3,509GBP
- Report
- February 2026
- 250 Pages
Global
From €4127EUR$4,490USD£3,509GBP
- Report
- April 2023
- 175 Pages
Global
From €5423EUR$5,899USD£4,610GBP
- Report
- August 2025
- 197 Pages
Global
From €3259EUR$3,545USD£2,771GBP
€3621EUR$3,939USD£3,079GBP
- Report
- August 2025
- 180 Pages
Global
From €3259EUR$3,545USD£2,771GBP
€3621EUR$3,939USD£3,079GBP
- Report
- May 2024
- 135 Pages
Global
From €3676EUR$3,999USD£3,125GBP
- Report
- May 2024
- 135 Pages
Global
From €3676EUR$3,999USD£3,125GBP
- Report
- March 2024
- 117 Pages
Global
From €3500EUR$4,079USD£3,080GBP
- Report
- October 2026
- 50 Pages
Global
From €2436EUR$2,650USD£2,071GBP

Moxifloxacin is an antibiotic used in the treatment of oncology drugs. It is a fourth-generation fluoroquinolone, which is a type of antibiotic that works by inhibiting bacterial DNA replication. Moxifloxacin is used to treat a variety of infections, including those caused by bacteria, viruses, and fungi. It is also used to treat certain types of cancer, such as leukemia and lymphoma. Moxifloxacin is generally well-tolerated and has few side effects.
Moxifloxacin is available in both oral and intravenous formulations. It is typically prescribed for short-term use, as long-term use can lead to the development of antibiotic resistance. The drug is also used in combination with other drugs to treat certain types of cancer.
The moxifloxacin market is highly competitive, with several companies offering the drug. Some of the major players in the market include Pfizer, Merck, Novartis, and AstraZeneca. Show Less Read more